Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Serum Institute of India

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2021

            Details:

            The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Live-attenuated SARS-CoV-2 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC

            Highest Development Status: Phase I Product Type: Vaccine

            Recipient: Codagenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2021

            Details:

            Designed as a randomized, double-blinded, placebo-controlled dose-escalation study, the Phase 1 trial will evaluate a total of 48 volunteers at multiple dose levels to determine the safety and tolerability COVI-VAC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVISHIELD

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 04, 2021

            Details:

            SII, which is developing Covishield is seeking emergency approval for its vaccine on the basis of the interim safety and immunogenicity data from the Phase 2 and 3 trials, along with the findings of overseas clinical studies done on 23,745 participants.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 10-Valent Pneumococcal Conjugate Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Pneumosil

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 28, 2020

            Details:

            The vaccine called PNEUMOSIL® will primarily help to fight against pneumococcal pneumonia amongst children and will be available at an affordable competitive price with an advantage of presence of serotypes 6A and 19A in the vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVI-VAC

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC

            Highest Development Status: Phase I Product Type: Vaccine

            Recipient: Codagenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            Codagenix and the Serum Institute of India announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Government of Bangladesh

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 05, 2020

            Details:

            5 million doses of ChAdOx1 nCoV-19 per month would be purchased through Bangladesh’s drug maker, Beximco Pharmaceuticals. Serum Institute would provide the vaccine at a price similar to that which India pays.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase II Product Type: Vaccine

            Recipient: ABEC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 29, 2020

            Details:

            ABEC’s Custom Single Run (CSR®) is supporting Serum Institute of India in delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 29, 2020

            Details:

            The expansion brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDX-005

            Therapeutic Area: Infections and Infectious Diseases Product Name: CDX-005

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Codagenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 16, 2020

            Details:

            Drugs Controller General of India (DCGI) to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.

            PharmaCompass